Private Equity - chance or risk for the health food industry?

Eike Zimbehl, Triodos finance GmbH, Helmy Abouleish, SEKEM Group, Ulrich walter, Ulrich walter GmbH, Volker of length fields, journalist and moderator, and Peter Blom, Triodos bank, discuss private Equity in the bio industry” to the topic “. (openPR) - Nuremberg, 19 February 2007l. The panel discussion within the framework that bio subject 2007 „private Equity in the bio market - It showed chances and risks for the increasing capital requirement in the health food industry “with experts from the health food industry and the international financial market that due to strong expansions a high capital requirement comes to the bio industry. Private Equity investor can be thereby strategic partners if the long-term objectives agree.

The bio industry in Germany is to a large extent characterized by small firms and medium-size enterprises, with which the capital is in the hands of the partners Geschäftsführer or the families. „This picture is reflected in Europe only partially against “, like that Peter Blom, Vorstandsvorsitzender of the Triodos bank group, in its inaugural address, „in the last years is some bio food manufacturers and - dealers European and world-wide sold to the stock exchange gone or to large market participants outside of the bio industry. “This development took up also the German financial market, then Deutsche Bank „S-box e.g. offers bio food index certificate “. Those are portions of shares of eight bio manufacturers and - dealers, under it e.g. Royal Wessanen (Allos, De Rit, Tartex + Dr. Ritter, Molenaartje, Zonnatura, Natudis), Hain Celestial (Natumi, Lima) and Whole Foods Markets - all together enterprises, that are familiar national and international bio consumers. With still two digit growth rates the future capital requirement of the bio industry cannot be achieved any longer alone by means of the conventional house bank financing. Also in view to the follow-up regulation and the intensified granting of credit guidelines for medium-size enterprises alternative financing models must, as e.g. private Equity is considered. With the fact it is important that the bio enterprises have a strong identity and traditions, which in a close relationship to economic success. They exhibit a high social responsibility in relation to coworkers, customers, suppliers and above all the environment.

The topic „private Equity in the bio market - Chances and risks for the increasing capital requirement in the health food industry “discussed also Ulrich walter, managing director Ulrich walter GmbH (Germany), Helmy Abouleish, managing director Sekem Group (Egypt) and Dr. Eike Zimbehl, managing director Triodos finance GmbH (Germany). Thus Ulrich walter estimated the medium-term capital requirement of the bio industry on up to 500 million euro and requested private Equity investor to argue more strongly with the industry and develop calculable door scenarios, because high net yields and warranty interest were not to be expected in the bio industry in the comparison e.g. to the technology industry. It confirmed however, which could be interesting in the future also private Equity investor for the bio enterprises, because apart from capital requirement to stabilization of own capital funds, for expansions or acquisitions also the topic Nachfolgereglung wins a ever higher meaning.
Also Helmy Abouleish gave information over the different financings of the capital requirement of the SEKEM Group. With the fact it stressed that it concerned financial investors, who specialized in the range „green money “and who industry and their development know and long-term to accompany. The holistic concept of the financing offers of the Triodos bank and also the GLS bank played a central role and also in the future this strategic and long-term partnership were continued.

Dr. Eike Zimbehl described the factors for a successful co-operation with private Equity investors. It stressed the necessity for entrepreneurs to realize first over their real motives and motives for a private Equity participation and attain with the financial investors over goals and door scenarios unanimity. At the same time place yourself for the bio enterprises the task and chance to develop the enterprise strategy more clearly and management information systems as well as Controlling professionalisieren. With the development of meaningful solutions the bank can offer as trusting partners a platform.

Press contact:
organic mark communication GmbH
Julia Hameister
Kasseler STR. 1a, 60486 Frankfurt
Telephone: +49 (0) 69,750 688-0
Mobil: +49 (0) 176 20 53 62 04
E-Mail: hameister@organic-werbeagentur.de
www.organic-press.de

Triodos bank NV
Thomas Steiner
Utrechtsweg 60, NL 3700 STARTING FROM Zeist
+31 (0) 30,693 65 20
+31 (0) 6,534 88813
thomas.steiner@triodos.nl
www.triodos.nl

Over the Triodos bank:
Since the establishment in the year 1980 the Triodos bank pursues ethical, social and financial goals according to „the three-way principle “: the consideration of the interests of humans, environment and economics. She is pioneer and an innovative, driving Kraft in the lasting banking transaction with locations in the Netherlands, Belgium, Great Britain, Spain and Germany. The Triodos bank offers short, central and long-term credits and project financings and is active for more than 10 years also into private Equity. The Triodos bank presented itself for the first time of 15. until 18 February 2007 on that bio subject 2007 (7/Stand 431 resounded) and was available for all questions approximately around lasting financing offers. More information under: www.triodos.com and www.triodos.de

Dieser Artikel wurde veröffentlicht auf
OpenPR - http://openpr.de/news/120887/Private-Equity-Chance-oder-Risiko-fuer-die-Naturkostbranche.html